Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
22.03.2017 22:48:00

Nuclear Medicine Equipment Market Analysis By Product (SPECT - Hybrid SPECT, Standalone SPECT; Hybrid PET; Planar Scintigraphy), By Application (Oncology, Cardiology, Neurology, General Imaging),...

NEW YORK, March 22, 2017 /PRNewswire/ -- The global nuclear medicine equipment market is expected to reach a value of USD 2.7 billion by 2025, according to a new report by Grand View Research, Inc. Nuclear medicine involves the utilization of radiation to diagnose diseases or treat them. It also involves determining whether specific organs are functioning normally. Over a stretch of the last two decades, rapid technological advancements in nuclear medicine have transformed the medicine practice.

With growing awareness about the importance of early diagnosis of chronic diseases, there has been a noticeable increase in diagnostic nuclear medicine procedures worldwide. This is evident from stats generated from developing countries, which represents about 26% of the world population. These countries conduct diagnostic nuclear medicine tests at a rate of 1.9% per year. In addition, in developed countries such as the U.S., the frequency of nuclear medicine procedures ranges to about 20 million per year. It is evident that the frequency of use of nuclear medicine and procedures involving radiopharmaceuticals in diagnosis is growing at over 10% per year, indicating a rise in adoption of nuclear medicine equipment worldwide. However, high cost associated with nuclear medicine equipment and insufficient reimbursement support for radiology is expected to hinder the growth of the market. In addition, a growing trend of purchasing refurbished systems for cost saving is expected to affect equipment sales of existing market players.

Further Key Findings From the Study Suggest:

The North American market is expected to register lucrative growth owing to increasing preference for SPECT and PET scans for diagnosis of chronic diseases

Growing awareness and government initiatives pertaining to usage of radiopharmaceuticals in the North American region is expected to boost usage rates. For instance, in December 2016, the FDA issued new guidelines to enforce FDA's proposed policies regarding compounding and repackaging of radiopharmaceuticals for human use in the U.S.

Oncology accounted for the largest market share in application segment in the year 2015 owing to the increasing incidence and prevalence of cancer worldwide

Asia Pacific market is expected to witness significant growth owing to Japan, China, and India where use of nuclear medicine is increasing at a fast pace. In addition, the usage of radioimmunotherapy-based targeted cancer treatment to counter incidence of cancer and cardiovascular diseases is aiding in the growth of the market

Some of the leading vendors operating in the nuclear medicine equipment market are GE Healthcare; Siemens Healthineers; Philips Healthcare; and Toshiba America Medical Systems.

The key players are focused on expansion & penetration opportunities in developing and emerging economies to achieve sustainable growth in the market
Read the full report: http://www.reportlinker.com/p04785518-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nuclear-medicine-equipment-market-analysis-by-product-spect---hybrid-spect-standalone-spect-hybrid-pet-planar-scintigraphy-by-application-oncology-cardiology-neurology-general-imaging-by-end-use-and-segment-forecasts-300428160.html

SOURCE Reportlinker

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!